Ergotamine/caffeine

Ergotamine/caffeine
Combination of
Ergotamine	vasoconstrictor, neurotransmitter agonist and antagonist
Caffeine	vasoconstrictor, phosphodiesterase inhibitor
Clinical data
Trade names	Cafergot, Migergot, others
AHFS/Drugs.com	Multum Consumer Information
MedlinePlus	a601048
License data	US DailyMed: Ergotamine and caffeine;
Pregnancy; category	AU: C; Contraindicated;
Routes of; administration	By mouth, rectal
ATC code	N02CA52 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	69063-86-1;
KEGG	D07600;

Ergotamine/caffeine, sold under the brand name Cafergot among others, is a fixed-dose combination medication used for the treatment of migraine. It contains ergotamine, as the tartrate, an alpha adrenergic blocking agent; and caffeine, a cranial vasoconstrictor.^[3]

Ergotamine/caffeine is available as a generic medication.

^ "Cafergot- ergotamine tartrate and caffeine tablet, film coated". DailyMed. U.S. National Library of Medicine. Archived from the original on 16 January 2014.
^ "Migergot- ergotamine tartrate and caffeine suppository". DailyMed. 29 November 2022. Retrieved 18 May 2024.
^ Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ (2002). "Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison". European Neurology. 47 (2): 99–107. doi:10.1159/000047960. PMID 11844898. S2CID 72629130.

[Cafergot_FDA_label-1] "Cafergot- ergotamine tartrate and caffeine tablet, film coated". DailyMed. U.S. National Library of Medicine. Archived from the original on 16 January 2014.

[Migergot_FDA_label-2] "Migergot- ergotamine tartrate and caffeine suppository". DailyMed. 29 November 2022. Retrieved 18 May 2024.

[pmid11844898-3] Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ (2002). "Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison". European Neurology. 47 (2): 99–107. doi:10.1159/000047960. PMID 11844898. S2CID 72629130.

[1]

[2]

[3]